26 completed, 7 recruiting, 4 not yet recruiting, 3 terminated. 41 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 41 | Completed 26, Recruiting 7, Not yet recruiting 4, Terminated 3, Withdrawn 1 |
| Phase 2 | 5 | Recruiting 2, Completed 1, Not yet recruiting 1, Terminated 1 |
Follow Tolerability: new trials by email Literature Review of Tolerability trials Research Report on Tolerability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-04-01 | 2026-07-30 |
| A First-in-Human SAD and MAD Study in HV to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-01-01 | 2026-10-16 |
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 42 | 2026-08-15 | 2026-10-15 |
| A Study of GensSci098 in Subjects With Graves' Disease GenSci098 - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 24 | 2025-11-21 | 2026-02-17 |
| A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) GenSci134, Placebo, Recombinant Human Growth Hormone Injection (Norditropin®) - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 64 | 2025-06-09 | 2026-04-14 |
| Single Ascending Dose and Multiple Ascending Dose Study of AVR-48 AVR-48, Placebo - Safety Issues, Tolerability | Phase 1 | Not yet recruiting | AyuVis Research, Inc. | 48 | 2025-06-01 | 2025-04-06 |
| A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults Nezavist SDD, Placebo - Healthy, Safety Evaluation of Escalating Doses | Phase 1 | Terminated | Lohocla Research Corporation | 29 | 2025-02-28 | 2026-09-08 |
| Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers. Placebo (SAD), RCS-21 (SAD), Placebo (MD) - Healthy Volunteers, Safety | Phase 1 | Recruiting | RNATICS GmbH | 32 | 2025-02-18 | 2026-10-26 |
| A Phase 1 Study of Y-3 in US Healthy Volunteers. Y-3 for injection, Placebo - Safety, Tolerability | Phase 1 | Completed | Neurodawn Pharmaceutical Co., Ltd. | 20 | 2025-02-04 | 2025-12-18 |
| Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors Test Product HY07121 - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 258 | 2024-10-24 | 2026-10-13 |
| A Study of GenSci098 in Subjects With Active Thyroid Eye Disease GenSci098, GenSci098 Placebo - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 76 | 2024-09-24 | 2026-02-11 |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation Test product: HYP-2090PTSA - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 257 | 2024-02-04 | 2026-01-29 |
| SB17170 Phase1 Trial in Healthy Volunteer SB17170, Placebo - Safety Issues, Tolerability | Phase 1 | Completed | SPARK Biopharma | 64 | 2023-05-24 | 2024-03-21 |
| Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers RHN-001 (one tablet 750mg), RHN-001 (750mg * 2 Tablets) - Safety, Tolerability | Phase 1 | Completed | RH Nanopharmaceuticals | 64 | 2023-03-09 | 2023-05-06 |
| Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers 5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo - Pharmacokinetics, Safety | Phase 1 | Completed | Usona Institute | 54 | 2022-12-27 | 2023-11-30 |
| Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam Linaprazan glurate, Drug drug interaction (DDI) - Clarithromycin (Part I), Drug drug interaction (DDI) - Midazolam (Part 2) - Safety Issues, Pharmacokinetics | Phase 1 | Completed | Cinclus Pharma Holding AB | 35 | 2022-11-27 | 2025-01-03 |
| Clinical Trial on Pharmacokinetics and Tolerability of AP707 AP707 - Pharmacokinetics, Tolerability | Phase 1 | Completed | CannaXan GmbH | 12 | 2022-03-02 | 2022-07-27 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants AZD7503, Placebo - Safety, Tolerability | Phase 1 | Completed | AstraZeneca | 56 | 2021-12-06 | 2025-02-19 |
| Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors IPG7236 - Safety Issues, Tolerability | Phase 1 / Phase 2 | Completed | Nanjing Immunophage Biotech Co., Ltd | 34 | 2021-11-15 | 2026-07-08 |
Showing 20 of 41. Sign in to see all of them.
Marijuana Abuse (2) · Neoplasms (2) · Respiratory Aspiration (2) · Alzheimer Disease (1) · Arthritis, Rheumatoid (1) · Dwarfism, Pituitary (1) · Dyskinesias (1) · Graves Disease (1) · Graves Ophthalmopathy (1) · Parkinson Disease (1) · Stroke (1) · Vaginosis, Bacterial (1)
Brain Diseases (4) · Central Nervous System Diseases (4) · Nervous System Diseases (4) · Autoimmune Diseases (3) · Endocrine System Diseases (3) · Immune System Diseases (3) · Mental Disorders (3) · Pathological Conditions, Signs and Symptoms (3) · Chemically-Induced Disorders (2) · Exophthalmos (2) · Eye Diseases (2) · Goiter (2) · Hyperthyroidism (2) · Musculoskeletal Diseases (2) · Neurodegenerative Diseases (2)
Injections (2) · ACT-462206 (1) · AZD-3043 (1) · AZD3839 (1) · AZD9819 (1) · AZD9977 (1) · Clarithromycin (1) · Didanosine (1) · Dronabinol (1) · Drug Interactions (1) · Enclomiphene (1) · Growth Hormone (1) · Human Growth Hormone (1) · Injections, Subcutaneous (1) · Methoxydimethyltryptamines (1)
AstraZeneca (8) · Changchun GeneScience Pharmaceutical Co., Ltd. (4) · Sichuan Huiyu Pharmaceutical Co., Ltd (3) · CannaXan GmbH (2) · Hangzhou Yirui Pharmaceutical Technology Co., Ltd (2) · Actelion (1) · AnaMar AB (1) · Astellas Pharma Europe B.V. (1) · AyuVis Research, Inc. (1) · Cinclus Pharma Holding AB (1) · Daiichi Sankyo (1) · Idorsia Pharmaceuticals Ltd. (1) · Laboratorios Sophia S.A de C.V. (1) · Lohocla Research Corporation (1) · Medigene AG (1)
United States (12) · China (8) · United Kingdom (7) · Germany (6) · Mexico (1) · Netherlands (1) · Pakistan (1) · South Korea (1) · Sweden (1)
Brendan Smyth (2) · Billings W Billings, MD (1) · Colleen Jensen (1) · Darren Wilbraham (1) · David Mathews, MD (1) · Dr Darren Wilbraham, MBBS DCPSA (1) · Dr Paul Bjornsson (1) · Huifang Zhou, PHD (1) · Izhar Hasan, MD, PhD (1) · Joseph S Podolski (1) · Karin Palm (1) · Li Zhang, Professor (1)
PMID 12750546, PMID 31601801, PMID 32087818, PMID 33148815, PMID 34487721, PMID 37185136, PMID 37832977, PMID 38258274, PMID 39858024
2015 (2), R44AA024905 (1)